

Frishta Nafeh, MPH
Centre on Drug Policy Evaluation, Toronto Canada

April 28, 2025

Background


- **Toxic drug poisoning** has been an ongoing public health challenge in Canada since national surveillance began in 2016.¹
- More than **50,000 drug toxicity deaths** have been reported since January 2016. These are primarily driven by unregulated fentanyl and its variable analogues.¹
- Canada's federal department of health funded the scale up of a harm-reduction oriented intervention known as safer supply.²
- Safer supply refers to providing **prescribed pharmaceutical-grade drugs** (e.g., opioids) as a safer **alternative to toxic unregulated drugs** to individuals at high risk of overdose.²
- Aims to reduce overdose risk by reducing reliance on toxic unregulated drugs.^{2,3}
- **Hydromorphone** tablets as **daily take-home** doses, coupled with a **long-acting opioid medication** (e.g., slow-release oral morphine) is the most common prescribing approach. Some programs provide prescribed alternatives without long-acting opioids (e.g., MySafe program).³
- Other programmatic variations include type of medications prescribed, dosing schedules, client monitoring, and integration with wraparound services.^{3,4}

Objective

We sought to synthesize the available literature on client experiences with safer supply programs to inform evidence-based prescribing, enhance service delivery, and guide future program implementation.


Methods


- Searched 7 electronic databases (MEDLINE, Embase, PsycINFO, CINAHL, EBM Reviews, Web of Science, & Scopus), and other sources (Google Scholar & National Safer Supply Community of Practice) between January 1, 2016, and August 21, 2024, for qualitative studies on safer supply client experiences.
- Data analysis guided by **Thomas and Harden's** 3-step thematic synthesis approach.⁵
- Used Critical Appraisal Skills Programme (CASP) checklist to assess the quality of included studies.⁶
- Confidence in review findings evaluated using **GRADE-CERQual**, 7 based on methodology, coherence, adequacy, and relevance.





- Our thematic synthesis included **19 peer-reviewed publications** (13 studies), involving **395** safer supply clients from British Columbia and Ontario, of whom 60% were men and 36% were women.
- Though not all studies reported ethnicity/race, the majority of participants were White (189; 48%) and around 91 (23%) participants were Indigenous.
- 135 inductively-derived codes → 12
 descriptive themes → 4 overarching analytic
 themes


CENTRE ON DRUG POLICY EVALUATION


























❖ Clients characterized safer supply programs as welcoming and non-judgmental, contrasting them with their previous experiences of feeling judged and mistrusted in conventional treatment programs (e.g., OAT). Clients valued the compassionate, respectful, and caring approach of safer supply staff.





❖ Clients participating in integrated safer supply models valued the access to a multidisciplinary team of care providers delivering a number of primary health care services alongside the prescription of opioid medications.



❖ Clients expressed a strong preference for being actively involved in decisions about their safer supply dosing and dispensation schedules to ensure the best possible outcomes tailored to their individual needs and goals.








Summary

- Need for wider range of opioid medications & formulation options to adequately support clients' varied & evolving needs.
- Client-centered and adaptive care approach—tailoring care to meet individual client needs & preferences rather than a uniform approach
 - > Goal-setting
 - Medications
 - > Dosing & dispensation schedule



Acknowledgements

Coauthors: Lucas Martignetti, Gillian Kolla, Matthew Bonn, Shahryar Moradi Falah Langeroodi, Karen Urbanoski, Bernie Pauly, Dan Werb, & Mohammad Karamouzian

Funder: Canadian Institutes of Health Research and Canada's Substance Use and Addictions Program
Canada Graduate Scholarship, Canadian Institutes of Health Research



Contact Information:

Frishta Nafeh <u>frishta.nafeh@mail.utoronto.ca</u>

References

- 1. Substance-related Overdose and Mortality Surveillance Task Group on behalf of the Council of Chief Medical Officers of Health. Ottawa: Public Health Agency of Canada; March 2025.
- 2. Government of Canada. *Safer Supply*. Available from: https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/safer-supply.html
- 3. Glegg, Stephanie, et al. "COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada." *Int J Drug Policy* 106 (2022): 103742.
- 4. Karamouzian, Mohammad, et al. "Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis." *Int J Drug Policy* 120 (2023): 104157.
- 5. Thomas, J., Harden, A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol* 8, 45 (2008).
- 6. Long, Hannah A., David P. French, and Joanna M. Brooks. "Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis." *Res Methods Med Health Sci*1.1 (2020): 31-42.
- 7. Lewin, Simon, et al. "Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series." *Implementation Sci* 13 (2018): 1-10.

Thanks so much for listening

Questions?